- Thermo Fisher Scientific unveils a new 72,500-square-foot clinical research laboratory building in Middleton, Wisconsin, enhancing its CMC analytical capabilities.
- The $58 million investment adds significant capacity, including advanced biosafety and molecular analysis facilities, to support drug development.
Thermo Fisher Scientific has expanded its clinical research capabilities with the unveiling of a new 72,500-square-foot laboratory building at its good manufacturing practices (GMP) site in Middleton, Wisconsin. This addition enhances the company’s chemistry, manufacturing, and control (CMC) analytical services, crucial for clinical development and laboratory services.
The new facility aims to support the development of life-changing medicines. Leon Wyszkowski, president of analytical services for clinical research at Thermo Fisher, said, “As research in biopharmaceutical therapies continues to rapidly expand, we are excited to expand our overall capacity and capabilities in laboratory services to help our customers deliver therapies that meet the highest quality and safety standards for patients.” The $58 million investment underscores Thermo Fisher’s commitment to its mission of making the world healthier, cleaner, and safer.
The GMP site in Middleton offers a comprehensive range of analytical services for small molecules and biologics. These include biopharmaceuticals, inhaled pharmaceuticals, device testing, cell and gene therapy, protein characterization, and mass spectrometry analysis across all phases of drug development.
The new building features a multi-use biosafety level 2 laboratory, dedicated spaces for liquid chromatography-mass spectrometry, protein characterization, molecular suites with controlled pre- and post-amplification labs, and large general-use labs. This expansion will also create jobs, adding up to 350 scientists and laboratory support professionals to the existing workforce of nearly 2,300 employees at the research campus.
Earlier this year, Thermo Fisher further enhanced its GMP services by adding biosafety testing at the Middleton facility. With the new laboratory building, the site now offers a full suite of end-to-end laboratory services, reinforcing its role in supporting the delivery of high-quality and safe biopharmaceutical therapies.
Overview of outsourcing trends 
